Brief: Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

FF EAI Robotics Ecosystem

07/11/2023 13:44

Nov 7 (Reuters) - Qualigen Therapeutics Inc  QLGN.O :
    * QUALIGEN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE
PHASE
1A CLINICAL TRIAL OF QN-302 FOR TREATMENT OF ADVANCED OR
METASTATIC SOLID TUMORS
    * QUALIGEN THERAPEUTICS INC - ANTICIPATES PROVIDING AN
UPDATE ON
SAFETY AND PRELIMINARY EFFICACY OF PHASE 1A STUDY IN FIRST HALF
OF 2024

Source text for Eikon:  ID:nGNXGNhBz 
Further company coverage:  QLGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))